Brainstorm Cell Therapeutics Faces Delisting Notice
Ticker: BCLI · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00005, $35 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Brainstorm Cell Therapeutics is on the brink of being delisted.
AI Summary
On January 15, 2025, Brainstorm Cell Therapeutics Inc. filed an 8-K report indicating a notice of delisting or failure to satisfy a continued listing rule. The company is based in New York and incorporated in Delaware.
Why It Matters
This filing signals potential delisting from an exchange, which could significantly impact the company's stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a severe risk to investors.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- January 15, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Business address city
FAQ
What specific listing rule or standard has Brainstorm Cell Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that has not been met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the immediate consequence of this 8-K filing for Brainstorm Cell Therapeutics?
The immediate consequence is the formal notification to the SEC and the public that the company is at risk of being delisted from its stock exchange.
Has Brainstorm Cell Therapeutics provided any details on steps being taken to rectify the situation?
This particular 8-K filing, as presented, does not contain information regarding specific steps the company is taking to address the delisting concerns.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 15, 2025.
What is the company's primary business sector based on its SIC code?
The company's Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 937 words · 4 min read · ~3 pages · Grade level 14.9 · Accepted 2025-01-15 16:22:50
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
- $35 million — ted Securities was below the minimum of $35 million required for continued listing on The N
Filing Documents
- tm253461d1_8k.htm (8-K) — 26KB
- 0001104659-25-003777.txt ( ) — 197KB
- bcli-20250115.xsd (EX-101.SCH) — 3KB
- bcli-20250115_lab.xml (EX-101.LAB) — 33KB
- bcli-20250115_pre.xml (EX-101.PRE) — 22KB
- tm253461d1_8k_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to Satisfy a Continued
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As Brainstorm Cell Therapeutics Inc. (the "Company") previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 19, 2024, on July 18, 2024, the Company received written notice (the "Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that from June 2, 2024 to July 17, 2024, the Company's Market Value of Listed Securities was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until January 14, 2025 (the "Compliance Date"), to regain compliance with the MVLS Requirement. On January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq's determination to delist the Company's common stock from The Nasdaq Capital Market by January 22, 2025, the Company's common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 24, 2025. While the Company intends to appeal Nasdaq's decision, no guarantee can be provided that it will be successful in doing so and that its common stock will continue to be listed on The Nasdaq Capital Market. A request for an appeal will stay the delisting of the Company's common stock pending Nasdaq's decision. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: January 15, 2025 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer